AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 FEB 4 - (NewsRx.com & NewsRx.net) -- Covalent Group, Inc., (CVGR) announced that it has signed a new contract with DynPort Vaccine Company, LLC, (DVC) for a phase I study in the development of a recombinant vaccine designed to provide protection against botulinum neurotoxin.
The $1.1 million contract value of this award was included in Covalent's new business announcement dated December 15, 2003.
Botulinum neurotoxins, known primarily for causing cases of foodborne botulism, are produced by the bacterium Clostridium botulinum and the related species Clostridium baratii and Clostridium butyricum. These bacteria produce seven distinct types of botulinum neurotoxins. Most cases of botulism occur when a person swallows a substance that contains the neurotoxin. The neurotoxin then passes through the gastrointestinal tract and into the blood until it eventually reaches peripheral nerve endings where it has the capability to paralyze muscles, including those needed to breathe. The ultimate result can be death.
Kenneth M. Borow, MD, Covalent ...
Source: HighBeam Research, $1.1M contract awarded to study counter-bioterrorism vaccine.